

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT

COLLABORATION AGREEMENT WITH SUZHOU BIOX

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company entered into a research results transformation collaboration agreement (研究成果轉化合作協議, the “**Collaboration Agreement**”) with Suzhou BioX Life Intelligence Industry Research Institute (蘇州BioX生命智能產業研究院) (“**Suzhou BioX**”) on March 6, 2021. According to the Collaboration Agreement, Suzhou BioX agreed to provide academic research services in relation to the application of AI technologies in genetic disease diagnosis and genetic counseling and the Company agreed to leverage our extensive industry experience to provide services for developing products based on the academic research results and intellectual properties of Suzhou BioX.

Suzhou BioX is a leading artificial intelligence research and industrial transformation platform focusing on life sciences and clinical genetics in China. To the best knowledge of the Directors, Suzhou BioX is an independent third party to our Company. The Company believes the collaboration with Suzhou BioX will help it stay abreast of the latest developments in the scientific community, which, in turn, helps ensure that the Company remains strategically conscious of where innovation is in the industry.

By Order of the Board

Suzhou Basecare Medical Corporation Limited

Dr. Liang Bo

Chairman and General Manager

Suzhou, PRC, March 8, 2021

As of the date of this announcement, the Board comprises Mr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors; Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors; and Mr. KANG Xixiong, Mr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive Directors.